A collaboration between Exact Sciences (EXAS) and the Mayo Clinic in identifying cancer biomarkers may have shown a way to potentially detect the most...
Exact Sciences (EXAS) said Friday that new research conducted by the company together with the Mayo Clinical demonstrated the ability of Cologuard to both...
Some of the stocks moving on news-driven events in Tuesday's after-hours include: STAF, +16.36% ARLO, +12.34% NUS, +10.58% TNDM, +7.64% AAPL, +4.65% VCYT,...
Exact Sciences (EXAS) shares fell more than 3% in extended trading on Tuesday after the molecular diagnostics company reported a wider-than-estimated Q1...
| Address | 441 Charmany Drive Madison, Wisconsin 53719 |
| Phone | +1.608.284.5700 |
| Number of Employees | 1,977 |
| Recent SEC Filing | 06/27/2019 11-K |
| Chairman, President & Chief Executive Officer | Kevin T. Conroy |
| Senior Vice President-Operations | Ana Hooker |
| Chief Financial Officer | Jeffrey T. Elliott |
| Co-Chief Medical Officer & Head-Medical Affairs | Barry M. Berger |
| Price Open | $115.05 |
| Previous Close | $116.34 |
| 52 Week Range | $47.78 - 121.98 |
| Market Capitalization | $15.0 B |
| Shares Outstanding | 129.1 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 07/30/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.76 |
| Beta vs. S&P 500 | N/A |
| Revenue | $454.5 M |
| Net Profit Margin | -41.58% |
| Return on Equity | -29.98% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
